School of Pharmacy, Shenyang Pharmaceutical University, Shenyang 110016, China.
The First Hospital, China Medical University, Department of Medical Oncology, Shenyang 110001, China.
Int J Pharm. 2022 Jul 25;623:121890. doi: 10.1016/j.ijpharm.2022.121890. Epub 2022 Jun 8.
It is well known that the difficulty of siRNA therapeutic application is the lack of safe and effective delivery vector. Virosome is a nano vesicle composed of lipid membrane and membrane protein. It retains fusion protein without virus genetic material, and therefore has the reduced immunogenicity compared with viral vector. Virosomes have the potential to deliver protein and nucleic acid drugs, but the traditional preparation method of virosomes is quite limited. In this study, we firstly proposed to synthesize influenza virus hemagglutinin HA2 virosomes by cell-free protein synthesis. In this study, liposomes provided the hydrophobic lipid bilayer environment for the formation of HA2 protein multimer, which inhibited the aggregation of hydrophobic HA2 and improved HA2 protein expression. Chitosan as a rigid core adsorbed siRNA and improved the encapsulation efficiency of siRNA. In conclusion, the cell-free protein synthesis was used to prepare HA2 virosomes, which paves the way for constructing a novel nano vector with high delivery efficiency and biosafety for the delivery of siRNA.
众所周知,siRNA 治疗应用的困难在于缺乏安全有效的递送载体。病毒体是由脂质膜和膜蛋白组成的纳米囊泡。它保留了融合蛋白而不含病毒遗传物质,因此与病毒载体相比,其免疫原性降低。病毒体具有递送蛋白质和核酸药物的潜力,但病毒体的传统制备方法相当有限。在本研究中,我们首次提出通过无细胞蛋白质合成来合成流感病毒血凝素 HA2 病毒体。在本研究中,脂质体为 HA2 蛋白多聚体的形成提供了疏水性脂质双层环境,抑制了疏水性 HA2 的聚集,提高了 HA2 蛋白的表达。壳聚糖作为刚性核心吸附 siRNA,提高了 siRNA 的包封效率。总之,无细胞蛋白质合成被用于制备 HA2 病毒体,为构建具有高递送效率和生物安全性的新型纳米载体以递送 siRNA 铺平了道路。